Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H27ClN2O.ClH |
Molecular Weight | 455.419 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2)CC(=O)C4=CC=C(Cl)C=C4
InChI
InChIKey=ZWZIQPOLMDPIQM-UHFFFAOYSA-N
InChI=1S/C26H27ClN2O.ClH/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29;/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3;1H
Lofepramine is a tricyclic antidepressant that is structurally similar to imipramine and is extensively metabolised to desipramine. In the absence of other major pharmacological effects it appears that its antidepressant activity stems from the facilitation of noradrenergic neurotransmission by uptake inhibition, and possibly by the additional facilitation of serotoninergic neurotransmission. The overall therapeutic efficacy of lofepramine is comparable to that of imipramine, amitriptyline, clomipramine, maprotiline and mianserin in patients with depression of varying severity, and coexisting anxiety. Lofepramine is a strong inhibitor of norepinephrine reuptake (Ki=5.4 nM) and a moderate inhibitor of serotonin reuptake (Ki=70 nM). It is a weak-intermediate level antagonist of the muscarinic acetylcholine receptors.Lofepramine is licensed for the treatment of depression in the United Kingdom.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
4.5 nM [IC50] | |||
Target ID: CHEMBL228 |
7.15 null [pKi] | ||
Target ID: CHEMBL222 |
8.27 null [pKi] | ||
Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3094050 |
285.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Lofepramine Approved UseLofepramine Tablets are used to treat the symptoms
of depression. Common symptoms include feelings of
worthlessness or deep sadness, difficulty with everyday
tasks, sleeping too much or not being able to sleep, and
feeling anxious. |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacological profile of antidepressants and related compounds at human monoamine transporters. | 1997 Dec 11 |
|
The effect of lofepramine and other related agents on the motility of Tetrahymena pyriformis. | 2002 Mar 10 |
|
Nonpharmacological treatments for anxiety disorders. | 2002 Sep |
|
The promises and pitfalls of reboxetine. | 2003 Winter |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder. | 2010 |
|
Tricyclic antidepressants and headaches: systematic review and meta-analysis. | 2010 Oct 20 |
Sample Use Guides
The recommended dose for adults is one tablet to
be taken 2 or 3 times a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3094050
The mean value for the inhibition constant (Ki) for lofepramine in human parotid gland was 285 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C87616
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
248-002-2
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
100000087617
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
m6884
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
31780
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
Y-39
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
Z24K96F991
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
DTXSID9047833
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
6294
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
26786-32-3
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
33611
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL87708
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY | |||
|
SUB02965MIG
Created by
admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD